About This Trial

Oral reversible BTK inhibitor for chronic ITP patients.

Primary Endpoints

  • Durable platelet response
  • Reduction in bleeding events

Latest Update

February 2026

Phase 2 showed 50% durable response rate. Potential first oral therapy for ITP.